Home About Us News Screening Diagnosis Treatment Patient Information Education
Contact Us
Educational Articles
Breast Cancer FAQs
Breast Self Exams
Breast Pain / Mastalgia
Gynecomastia
BRCA Testing
Fibrocystic Breast Changes
Open Breast Biopsies
Benefits of SAVI
Molecular Subtyping
Adjuvant Therapy
HALO Breast Pap Test
Inflammatory Breast Cancer
Locally Advanced Breast Cancer
Radiation Treatment for Early Stage
Sentinel Lymph Node Biopsy
Stereotactic Core Needle Biopsy
Non-Invasive Breast Cancer
No Prissy Shoes
Clinical Trials
American Society of Breast Surgery Mammo
University of Louisville Sentinel Lymph
NSABP, B39, B40 Clinical Trials
Taylor Rx Trial
Types of Breast Cancer
In Situ Breast Cancer
Invasive Breast Cancer
Locally Advanced Breast Cancer
Inflammatory Breast Cancer
Metastatic Breast Cancer
Frequently Asked Questions
What is Breast Pain/Mastalgia?
What is Lobular Carcinoma is Situ?
What is Atypical Ductal Hyperplasia?
What are Estrogen and Progesterone recep
What is the HER-2/neu test?
What is Whole Breast Irradiation?
What is Partial Breast Irradiation?
What are the reconstruction options?
Why do we give chemotherapy?
What is Tamoxifen?
What Is Ductal Carcinoma in Situ?
Are there prognostic indicators?
Are there different types?
What is Nipple Discharge?
What is Breast Cancer?
How does Breast Cancer spread?
Who gets Breast Cancer?
What are the chances?
Does race play a role in incidence?
What are fibrocystic changes?
What are the physical signs?
How is Breast Cancer staged?
What are the Aromatase inhibitors?
Diagnosis
Screening
Treatment
Taylor Rx Trial
The Trial Assigning IndividuaLized Options for Treatment (Rx), or TAILORx, was launched in 2006 to examine whether genes that are frequently associated with risk of recurrence for women with early-stage breast cancer can be used to assign patients to the most appropriate and effective treatment. TAILORx is sponsored by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), and is coordinated by the Eastern Cooperative Oncology Group (ECOG). All of the NCI-sponsored clinical trials groups* that perform breast cancer research studies have collaborated in the trial's development and are participating in this study.

TAILORx will determine the most effective current approach to cancer treatment, with the fewest side effects, for women with early-stage breast cancer by using Oncotype DXTM, a validated diagnostic test developed by Genomic Health, Inc., Redwood  City, Calif., in collaboration with the National Surgical Adjuvant Breast and Bowel Project (NSABP), a network of cancer research professionals. TAILORx is the first trial to be launched as part of a new NCI program, the Program for the Assessment of Clinical Cancer Tests (PACCT), which seeks to individualize cancer treatment by using, evaluating and improving the latest diagnostic tests.


(http://www.cancer.gov/newscenter/pressreleases/2006/tailorxrelease)
hello